Brought to you by 
Affimed signs innate cell antibody engager deal with Genentech
01 Jul 2020
Executive Summary
Affimed NV and Roche’s Genentech Inc. agreed to discover and conduct early- and late-stage research on innate immune cell--natural killer (NK) cell and T-cell--immunotherapies against certain Genentech-selected targets for various solid and hematological tumors. Genentech will take over clinical development and hold exclusive global commercialization rights; it is also responsible for related costs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Affimed signs innate cell antibody engager deal with Genentech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice